{
    "root": "7ec5dc95-1078-4483-80b2-7a1e0266640b",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Pregabalin",
    "value": "20240830",
    "ingredients": [
        {
            "name": "PREGABALIN",
            "code": "55JG375S6M",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_64356"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5291"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16189"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50821"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32035"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "METHYLPARABEN",
            "code": "A2I8C7HI9T",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_31835"
        },
        {
            "name": "PROPYLPARABEN",
            "code": "Z8IX2SC1OH",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32063"
        },
        {
            "name": "SODIUM PHOSPHATE, DIBASIC, ANHYDROUS",
            "code": "22ADO53M6F",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_37586"
        },
        {
            "name": "SUCRALOSE",
            "code": "96K6UQ3ZD4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32159"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        }
    ],
    "indications": {
        "text": "pregabalin indicated : \u2022management neuropathic pain associated diabetic peripheral neuropathy \u2022management postherpetic neuralgia \u2022adjunctive therapy treatment partial-onset seizures patients 1 month age older \u2022management fibromyalgia \u2022management neuropathic pain associated spinal cord injury",
        "doid_entities": [
            {
                "text": "peripheral neuropathy (DOID:574)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_574"
            },
            {
                "text": "neuropathy (DOID:870)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_870"
            },
            {
                "text": "fibromyalgia (DOID:631)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_631"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "\u2022 adult , begin dosing 150 mg/day . partial-onset seizure dosing pediatric patients 1 month age older , refer section 2.4 . ( 2.2 , 2.3 , 2.4 , 2.5 , 2.6 ) \u2022 dosing recommendations : indication dosing regimen maximum dose dpn pain ( 2.2 ) 3 divided doses per day 300 mg/day within 1 week . phn ( 2.3 ) 2 3 divided doses per day 300 mg/day within 1 week . maximum dose 600 mg/day . adjunctive therapy partial-onset seizures pediatric adult patients weighing 30 kg ( 2.4 ) 2 3 divided doses per day maximum dose 600 mg/day . adjunctive therapy partial-onset seizures pediatric patients weighing less 30 kg ( 2.4 ) 1 month less 4 years : 3 divided doses per day 4 years older : 2 3 divided doses per day 14 mg/kg/day . fibromyalgia ( 2.5 ) 2 divided doses per day 300 mg/day within 1 week . maximum dose 450 mg/day . neuropathic pain associated spinal cord injury ( 2.6 ) 2 divided doses per day 300 mg/day within 1 week . maximum dose 600 mg/day . \u2022 dose adjusted adult patients reduced renal function . ( 2.7 )",
        "doid_entities": [
            {
                "text": "fibromyalgia (DOID:631)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_631"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "25 mg capsules : white , hard-gelatin capsule printed black ink \u201c pfizer \u201d cap , \u201c pgn \u201d \u201c 25 \u201d body ; available : bottles 90 : ndc 59762-1342-1 50 mg capsules : white , hard-gelatin capsule printed black ink \u201c pfizer \u201d cap , \u201c pgn \u201d \u201c 50 \u201d ink band body , available : bottles 90 : ndc 59762-1344-1 75 mg capsules : white/orange hard gelatin capsule printed black ink \u201c pfizer \u201d cap , \u201c pgn \u201d \u201c 75 \u201d body ; available : bottles 90 : ndc 59762-1346-1 100 mg capsules : orange , hard-gelatin capsule printed black ink \u201c pfizer \u201d cap , \u201c pgn \u201d \u201c 100 \u201d body , available : bottles 90 : ndc 59762-1348-1 150 mg capsules : white hard gelatin capsule printed black ink \u201c pfizer \u201d cap , \u201c pgn \u201d \u201c 150 \u201d body , available : bottles 90 : ndc 59762-1351-1 200 mg capsules : light orange hard gelatin capsule printed black ink \u201c pfizer \u201d cap , \u201c pgn \u201d \u201c 200 \u201d body , available : bottles 90 : ndc 59762-1354-1 300 mg capsules : white/orange hard gelatin capsule printed black ink \u201c pfizer \u201d cap , \u201c pgn \u201d \u201c 300 \u201d body , available : bottles 90 : ndc 59762-1364-1 20 mg/ml oral solution : 16 fluid ounce white high density polyethylene ( hdpe ) bottle polyethylene-lined closure : 16 fluid ounce bottle ndc 59762-1576-1 storage handling store 25\u00b0c ( 77\u00b0f ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) ( usp controlled room temperature ) .",
    "adverseReactions": "pregabalin contraindicated patients known hypersensitivity pregabalin components . angioedema hypersensitivity occurred patients receiving pregabalin therapy [ ( 5.2 ) ] .",
    "indications_original": "Pregabalin is indicated for:\n                  \n                     \n                        \u2022Management of neuropathic pain associated with diabetic peripheral neuropathy\n                     \n                        \u2022Management of postherpetic neuralgia\n                     \n                        \u2022Adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older\n                     \n                        \u2022Management of fibromyalgia\n                     \n                        \u2022Management of neuropathic pain associated with spinal cord injury",
    "contraindications_original": "\u2022 For adult indications, begin dosing at 150 mg/day. For partial-onset seizure dosing in pediatric patients 1 month of age and older, refer to section 2.4 . ( 2.2 , 2.3 , 2.4 , 2.5 , 2.6 ) \u2022 Dosing recommendations: INDICATION Dosing Regimen Maximum Dose DPN Pain ( 2.2 ) 3 divided doses per day 300 mg/day within 1 week. PHN ( 2.3 ) 2 or 3 divided doses per day 300 mg/day within 1 week. Maximum dose of 600 mg/day. Adjunctive Therapy for Partial-Onset Seizures in Pediatric and Adult Patients Weighing 30 kg or More ( 2.4 ) 2 or 3 divided doses per day Maximum dose of 600 mg/day. Adjunctive Therapy for Partial-Onset Seizures in Pediatric Patients Weighing Less than 30 kg ( 2.4 ) 1 month to less than 4 years: 3 divided doses per day 4 years and older: 2 or 3 divided doses per day 14 mg/kg/day. Fibromyalgia ( 2.5 ) 2 divided doses per day 300 mg/day within 1 week. Maximum dose of 450 mg/day. Neuropathic Pain Associated with Spinal Cord Injury ( 2.6 ) 2 divided doses per day 300 mg/day within 1 week. Maximum dose of 600 mg/day. \u2022 Dose should be adjusted in adult patients with reduced renal function. ( 2.7 )",
    "warningsAndPrecautions_original": "25 mg capsules:\n                  \n                  White, hard-gelatin capsule printed with black ink \u201cPfizer\u201d on the cap, \u201cPGN\u201d over \u201c25\u201d on the body; available in:\n                  Bottles of 90:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0NDC 59762-1342-1\n                  \n                     50 mg capsules:\n                  \n                  White, hard-gelatin capsule printed with black ink \u201cPfizer\u201d on the cap, \u201cPGN\u201d over \u201c50\u201d and an ink band on the body, available in:\n                  Bottles of 90:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0NDC 59762-1344-1\n                  \n                     75 mg capsules:\n                  \n                  White/orange hard gelatin capsule printed with black ink \u201cPfizer\u201d on the cap, \u201cPGN\u201d over \u201c75\u201d on the body; available in:\n                  Bottles of 90:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0NDC 59762-1346-1\n                  \n                     100 mg capsules:\n                  \n                  Orange, hard-gelatin capsule printed with black ink \u201cPfizer\u201d on the cap, \u201cPGN\u201d over \u201c100\u201d on the body, available in:\n                  Bottles of 90:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0NDC 59762-1348-1\n                  \n                     150 mg capsules:\n                  \n                  White hard gelatin capsule printed with black ink \u201cPfizer\u201d on the cap, \u201cPGN\u201d over \u201c150\u201d on the body, available in:\n                  Bottles of 90:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0NDC 59762-1351-1\n                  \n                     200 mg capsules:\n                  \n                  Light orange hard gelatin capsule printed with black ink \u201cPfizer\u201d on the cap, \u201cPGN\u201d over \u201c200\u201d on the body, available in:\n                  Bottles of 90:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0NDC 59762-1354-1\n                  \n                     300 mg capsules:\n                  \n                  White/orange hard gelatin capsule printed with black ink \u201cPfizer\u201d on the cap, \u201cPGN\u201d over \u201c300\u201d on the body, available in:\n                  Bottles of 90:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0NDC 59762-1364-1\n                  \n                     20 mg/mL oral solution:\n                  \n                  16 fluid ounce white high density polyethylene (HDPE) bottle with a polyethylene-lined closure:  \n                  16 fluid ounce bottle\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0NDC 59762-1576-1\n                  Storage and Handling\n                  Store at 25\u00b0C (77\u00b0F); excursions permitted to 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F) (see USP Controlled Room Temperature).",
    "adverseReactions_original": "Pregabalin is contraindicated in patients with known hypersensitivity to pregabalin or any of its components. Angioedema and hypersensitivity reactions have occurred in patients receiving pregabalin therapy [see Warnings and Precautions (5.2)].",
    "drug": [
        {
            "name": "Pregabalin",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_64356"
        }
    ]
}